HC Wainwright Reiterates Buy Rating for Affimed (NASDAQ:AFMD)

Affimed (NASDAQ:AFMD)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 187.36% from the company’s current price.

Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Affimed in a research note on Monday, September 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.00.

Affimed Stock Down 4.7 %

Shares of AFMD opened at $3.48 on Friday. The company has a quick ratio of 2.71, a current ratio of 2.71 and a debt-to-equity ratio of 0.13. The firm’s 50 day moving average is $3.49 and its 200-day moving average is $4.52. Affimed has a 12 month low of $2.92 and a 12 month high of $8.95.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $1.67 million. Affimed had a negative return on equity of 155.30% and a negative net margin of 2,922.74%. On average, analysts expect that Affimed will post -4.25 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. boosted its stake in shares of Affimed by 4.6% in the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after purchasing an additional 15,108 shares in the last quarter. Intellectus Partners LLC lifted its stake in Affimed by 12.2% in the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. FMR LLC boosted its position in Affimed by 30.0% in the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after buying an additional 4,086 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Affimed during the third quarter worth $44,000. Finally, Choreo LLC acquired a new position in shares of Affimed during the second quarter worth $54,000. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.